Release Date: March 14, 2025
Expiration Date: March 14, 2026
Time to Complete Activity: 1.0 hour

Faculty

Arshad M. Khanani, MD, MA, FASRS
Clinical Professor
University of Nevada, Reno School of Medicine
Managing Partner, Director of Clinical Research, Director of Fellowship
Sierra Eye Associates
Reno, NV

Carl D. Regillo, MD, FACS 
Director, Retina Service
Wills Eye Hospital
Partner, Mid Atlantic Retina
Professor of Ophthalmology
Thomas Jefferson University
Philadelphia, PA
 

Target Audience 

This activity has been designed to meet the educational needs of retina specialists and comprehensive ophthalmologists. It may also benefit other clinicians who are involved in the care of patients with retinal vascular diseases.
 

Educational Provider 

This activity is provided by Paradigm Medical Communications, LLC.  
 

Supporter Acknowledgment 

This activity is supported by an educational grant from Genentech, a member of the Roche Group.
 

Program Overview 

The potential for extended durability is just the tip of the iceberg when considering the use of faricimab or aflibercept 8 mg. In this point-counterpoint activity, experts will get beneath the surface to discuss factors that can be used to refine and individualize treatment choice and retreatment decisions with the use of second-generation therapies. This includes differences in their mechanisms of action, clinical trial designs, effects on clinical biomarkers of disease activity, and (in some cases) the potential to reverse disease.
 

Learning Objectives

Upon completion of this activity, participants should be able to:

• Compare the efficacy of second-generation therapies for retinal vascular diseases in terms of impact on anatomic markers of disease 
• Discuss differences in the clinical trial designs that can affect outcome interpretation regarding second-generation therapies indicated for retinal vascular diseases
• Devise appropriate treatment plans for patients with treatment-naïve or previously treated neovascular age-related macular degeneration, diabetic macular edema, and retinal vein occlusion based on the latest evidence

Physician Accreditation Statement

Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
 

Physician Credit Designation Statement

Paradigm Medical Communications, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

PA Continuing Education 

PAs may claim a maximum of 1.0 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
 

Nurse Practitioner Continuing Education 

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
 

Hardware/Software Requirements

This accredited CME activity is designed using HTML5 web components. As you navigate the video using the supplied controls, the slides will sync to the speaker.

Supported Browsers (Desktop/Mobile)
Chrome 45+, Firefox 40+, Edge, Edge Chromium, Safari 8+, Opera 31+

PDF documents
This activity may contain PDF documents. Most current browsers support viewing of PDFs natively, but you may also download a free version of Adobe Acrobat Reader here: http://get.adobe.com/reader

Technical Support
If you have any technical problems or playback issues, email us at contactus@paradigmmc.com.
 

Instructions for Participation

To receive a certificate and claim credit, participants must:

• Follow instructions to register or log in with your professional information and complete the pretest
• View the online activity in its entirety
• Complete and submit the online posttest and evaluation. You must answer 70% of the posttest questions correctly to earn credit. You will have unlimited opportunities to successfully complete the posttest

A certificate of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation.

For questions regarding CME credit, contact the Paradigm CME Department at cme@paradigmmc.com.

There are no fees for participating in this activity.
 

Disclosure of Relevant Financial Relationships

In accordance with the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education, Paradigm requires that all planners, faculty, and others who are in a position to control the content of this activity disclose all financial relationships with ineligible companies during the past 24 months.

All relevant relationships are identified and mitigated according to Paradigm policy prior to individuals assuming their roles and are disclosed prior to learners’ engagement in the activity. Paradigm is committed to providing learners with high-quality accredited continuing education that promotes improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The content of this activity was independently reviewed to ensure that it is fair and balanced, scientifically rigorous, evidence based, and aligned with the public interest. All relevant relationships have been mitigated.

Arshad M. Khanani, MD, MA, FASRS
Consultant: 4D Molecular Therapeutics; AbbVie Inc; ADARx Pharmaceuticals, Inc.; Adverum Biotechnologies, Inc; Alcon; Alkeus Pharmaceuticals, Inc; Allgenesis Biotherapeutics;  Amgen Inc; Annexin Pharmaceuticals; Annexon, Inc; Apellis Pharmaceuticals, Inc; Ashvattha Therapeutics; Astellas Pharma US, Inc; Aviceda Therapeutics; Beacon Therapeutics; Boehringer Ingelheim International GmbH; Clearside BioMedical; Complement Therapeutics Ltd; Exegenesis Bio Co; EyePoint Pharmaceuticals, Inc; F. Hoffmann-La Roche AG; Frontera Therapeutics, Inc.; Genentech, Inc; Gyroscope Therapeutics Limited; Harrow, Inc.; InFocus Therapeutics, Inc.; i-Lumen Scientific; IVERIC bio, Inc; Janssen Pharmaceuticals, Inc; Kodiak Sciences Inc; Kriya Therapeutics; Kyowa Kirin Co. Ltd.; Merit Pharmaceutical; Nanoscope Therapeutics, Inc; Neurotech Pharmaceuticals, Inc; Novartis AG; Ocular Therapeutix, Inc; Oculis; Ocuphire Pharma, Inc; OcuTerra Therapeutics; Olive BioPharma; Ollin Biosciences, Inc.; Opthea; Opus Genetics, Inc.; Oxular; Oxurion NV; Perfuse Therapeutics; Ray Therapeutics; RecensMedical Inc; Regeneron Pharmaceuticals Inc; REGENXBIO Inc; Revive Therapeutics; RevOpsis Therapeutics LLC; Samsung Biologics; Sanofi; Stealth BioTherapeutics Inc; Surrozen; Thea Pharma Inc; Therini Bio, Inc.; UNITY Biotechnology; Vanotech; Vial; ZipBio
Research Funding: 4D Molecular Therapeutics; Adverum Biotechnologies, Inc; Alexion Pharmaceuticals, Inc; Annexon, Inc; Apellis Pharmaceuticals, Inc; Astellas Pharma US, Inc; Aviceda Therapeutics; Complement Therapeutics Ltd; Exegenesis Bio Co; EyePoint Pharmaceuticals, Inc; F. Hoffmann-La Roche AG;  Genentech, Inc; Gyroscope Therapeutics Limited; IVERIC bio, Inc; Janssen Pharmaceuticals, Inc; Kodiak Sciences Inc; Kyowa Kirin Co. Ltd.; Neurotech Pharmaceuticals, Inc; Ocular Therapeutix; Oxular; REGENXBIO Inc; Sanofi; Vanotech
Stocks: Ashvattha Therapeutics; Aviceda Therapeutics; Oculis; Opthea; Perfuse Therapeutics; PolyPhotonix Medical Ltd; RecensMedical, Inc; RevOpsis Therapeutics; Vial; ZipBio
Other (Board of Directors): Oculis

Carl D. Regillo, MD, FACS 
Consultant: 4D Molecular Therapeutics; Adverum Biotechnologies, Inc; Alcon; agtc; Allergan, Inc.; Annexon, Inc; Apellis Pharmaceuticals, Inc; Aviceda Therapeutics; Bausch & Lomb; BioCryst Pharmaceuticals, Inc.; Boehringer Ingelheim International GmbH; Breye Therapeutics ApS; Clearside Biomedical; Chengdu Kanghong Pharmaceutical Group Co, LTD; Cognition Therapeutics; Endogena Therapeutics Inc; EyePoint Pharmaceuticals, Inc; Genentech, Inc; IVERIC bio, Inc; Janssen Pharmaceuticals, Inc; Kodiac Sciences Inc; Lineage Cell Therapeutics, Inc; Merck & Co, Inc; Neurotech Pharmaceuticals, Inc; NGM Biopharmaceuticals; Novartis AG; Ocugen, Inc.; Oculis; Ocuphire Pharma, Inc; OcuTerra Therapeutics; Opthea; Ora, Inc.; Orasis Pharmaceuticals; Ray Therapeutics; REGENXBIO Inc; Stealth BioTherapeutics Inc; Thea Pharma Inc; Viatris Inc.; ZEISS International; ZipBio
Research Funding: 4D Molecular Therapeutics; Adverum Biotechnologies, Inc; Allergan, Inc.; Annexon, Inc; Apellis Pharmaceuticals, Inc; Astellas Pharma US, Inc; EyeBio; EyePoint Pharmaceuticals, Inc; Genentech, Inc; Gyroscope Therapeutics Limited; IVERIC bio, Inc; Janssen Pharmaceuticals, Inc; Kodiac Sciences Inc; Lineage Cell Therapeutics, Inc; NGM Biopharmaceuticals; Notal Vision, Inc; Novartis AG; Ocugen, Inc; OcuTerra Therapeutics; Opthea; Regeneron Pharmaceuticals Inc; REGENXBIO Inc
Stocks: Aviceda Therapeutics; Ocugen, Inc.; ZipBio

Paradigm Medical Communications, LLC staff members have no relevant financial relationships with ineligible companies to disclose.

Peer Reviewer
Stock: CytomX Therapeutics Inc (expired 1/25); F. Hoffmann-La Roche Ltd (expired 3/24); Medtronic (expired 3/24); Pfizer Inc. (expired 3/24)
 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.

Disclaimer

This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.

As an ACCME-accredited provider, Paradigm Medical Communications, LLC must ensure that its activities include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC. 

Terms of Use and Privacy Policy
Disclaimer
The materials provided for this activity are for informational purposes only and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC. Paradigm Medical Communications, LLC accepts no liability for the content referenced in this activity.

Privacy policy
Paradigm Medical Communications, LLC or hosted contracted partner is committed to protecting the privacy of those who participate in the activities located at www.paradigmmc.com (herein referred to as “website”). The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.

Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.

Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC to continuously improve the learning experience.

Paradigm Medical Communications, LLC does not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC staff members review individual test results to the extent necessary to record and track participants’ credits.

Contact Us

If you have any questions or comments, please email us at contactus@paradigmmc.com.

© 2025 Paradigm Medical Communications, LLC except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.